---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-029913"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:54:07.924445+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics Chief Legal Officer Tamara Joseph to depart March 6, 2024

## Summary
- Tamara Joseph, Chief Legal Officer and Corporate Secretary, is leaving effective March 6, 2024 to pursue other interests.
- Severance includes continuation of base salary for nine months totaling $356,298.75, plus prorated cash bonus of $34,266.98.
- Joseph will provide consulting services on an hourly as-needed basis for nine months at $395/hour; stock options and RSUs continue vesting.
- Separation and Consulting Agreement entered February 9, 2024; full terms to be filed with Form 10-K.

## SEC filing metadata
- accession: 0001193125-24-029913
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/0001193125-24-029913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/d45988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-029913
- JSON: https://secwatch.observer/filing/0001193125-24-029913.json
- Plain text: https://secwatch.observer/filing/0001193125-24-029913.txt

## Key facts
- Executive change
  Tamara Joseph departed as Chief Legal Officer and Corporate Secretary at Spero Therapeutics, Inc..
  - Action: stepping down
  - Role: Chief Legal Officer and Corporate Secretary
  source text: Tamara Joseph, the Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc. (the “Company”), is stepping down from that position to pursue other interests, effective as of March 6, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/0001193125-24-029913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.